Klaus Bendtzen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Klaus Bendtzen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ferdinando Nicoletti
IRCCS Neuromed, 86077 Pozzilli, Italy
2 shared publications - Paolo Fagone
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
2 shared publications - Carmelo Iacobello
Unit of Infectious Diseases, AOE “Cannizzaro”, 95126 Catania, Italy
1 shared publication Casper Steenholdt
Department of Gastroenterology, Herlev Hospital, Copenhagen, Denmark
1 shared publication- Casper Steenholdt
Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark
1 shared publication - Concetta Ilenia Palermo
Department of Biomedical and Biotechnological Sciences University of Catania 95123 Catania Italy
1 shared publication
Latest Publications
- Open Access
Evaluation of Toll-like Receptor 4 (TLR4) Involvement in Human Atrial Fibrillation: A Computational Study
In the present study, we have explored the involvement of Toll-like Receptor 4 (TLR4) in atrial fibrillation (AF), by using a meta-analysis of publicly available human transcriptomic data. The meta-analysis revealed 565 upregulated and 267 downregulated differentially expressed genes associated with AF. Pathway enrichment analysis highlighted a significant overrepresentation in immune-related pathways for the upregulated genes. A significant overlap between AF differentially expressed genes and TLR4-modulated genes was also identified, suggesting the potential role of TLR4 in AF-related transcriptional changes. Additionally, the analysis of other Toll-like receptors (TLRs) revealed a significant association with TLR2 and TLR3 in AF-related gene expression patterns. The examination of MYD88 and TICAM1, genes associated with TLR4 signalling pathways, indicated a significant yet nonspecific enrichment of AF differentially expressed genes. In summary, this study offers novel insights into the molecular aspects of AF, suggesting a pathophysiological role of TLR4 and other TLRs. By targeting these specific receptors, new treatments might be designed to better manage AF, offering hope for improved outcomes in affected patients.
Open AccessEvaluation of Toll-like Receptor 4 (TLR4) Involvement in Human Atrial Fibrillation: A Computational Study
In the present study, we have explored the involvement of Toll-like Receptor 4 (TLR4) in atrial fibrillation (AF), by using a meta-analysis of publicly available human transcriptomic data. The meta-analysis revealed 565 upregulated and 267 downregulated differentially expressed genes associated with AF. Pathway enrichment analysis highlighted a significant overrepresentation in immune-related pathways for the upregulated genes. A significant overlap between AF differentially expressed genes and TLR4-modulated genes was also identified, suggesting the potential role of TLR4 in AF-related transcriptional changes. Additionally, the analysis of other Toll-like receptors (TLRs) revealed a significant association with TLR2 and TLR3 in AF-related gene expression patterns. The examination of MYD88 and TICAM1, genes associated with TLR4 signalling pathways, indicated a significant yet nonspecific enrichment of AF differentially expressed genes. In summary, this study offers novel insights into the molecular aspects of AF, suggesting a pathophysiological role of TLR4 and other TLRs. By targeting these specific receptors, new treatments might be designed to better manage AF, offering hope for improved outcomes in affected patients.
- Open Access
Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) has posed a serious threat to global health. As no specific therapeutics are yet available to control disease evolution, more in-depth understanding of the pathogenic mechanisms induced by SARS-CoV-2 will help to characterize new targets for the management of COVID-19. The present study identified a specific set of biological pathways altered in primary human lung epithelium upon SARS-CoV-2 infection, and a comparison with SARS-CoV from the 2003 pandemic was studied. The transcriptomic profiles were also exploited as possible novel therapeutic targets, and anti-signature perturbation analysis predicted potential drugs to control disease progression. Among them, Mitogen-activated protein kinase kinase (MEK), serine-threonine kinase (AKT), mammalian target of rapamycin (mTOR) and I kappa B Kinase (IKK) inhibitors emerged as candidate drugs. Finally, sex-specific differences that may underlie the higher COVID-19 mortality in men are proposed.
Open AccessTranscriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) has posed a serious threat to global health. As no specific therapeutics are yet available to control disease evolution, more in-depth understanding of the pathogenic mechanisms induced by SARS-CoV-2 will help to characterize new targets for the management of COVID-19. The present study identified a specific set of biological pathways altered in primary human lung epithelium upon SARS-CoV-2 infection, and a comparison with SARS-CoV from the 2003 pandemic was studied. The transcriptomic profiles were also exploited as possible novel therapeutic targets, and anti-signature perturbation analysis predicted potential drugs to control disease progression. Among them, Mitogen-activated protein kinase kinase (MEK), serine-threonine kinase (AKT), mammalian target of rapamycin (mTOR) and I kappa B Kinase (IKK) inhibitors emerged as candidate drugs. Finally, sex-specific differences that may underlie the higher COVID-19 mortality in men are proposed.
- 2 February 2017
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 45 (5) , 759-760
Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?
Linked ContentThis article is linked to Ungar et al and Ben‐Horin et al papers. To view these articles visit https://doi.org/10.1111/apt.13862 and https://doi.org/10.1111/apt.13932.
- 2 February 2017
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 45 (5) , 759-760
Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?
Linked ContentThis article is linked to Ungar et al and Ben‐Horin et al papers. To view these articles visit https://doi.org/10.1111/apt.13862 and https://doi.org/10.1111/apt.13932.
- 14 May 2015
- Published by BMJ in Frontline Gastroenterology
- Vol. 7 (2) , 152-154
Monitoring immunogenicity of protein-based TNF antagonists
- 14 May 2015
- Published by BMJ in Frontline Gastroenterology
- Vol. 7 (2) , 152-154
Monitoring immunogenicity of protein-based TNF antagonists
- Open Access
- 8 April 2015
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 6, 152
Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence
Specific inhibition of the cytokine, tumor necrosis factor-α (TNF), has revolutionized the treatment of patients with several autoimmune diseases, and genetically engineered anti-TNF antibody constructs now constitute a heavy medicinal expenditure. All currently used anti-TNF biopharmaceuticals may lower disease activity and, in some patients, induce remission. Unfortunately, not all patients respond adequately, and safety may be compromised by immunogenicity with the induction of anti-drug-antibodies (ADA). Assessment of drug pharmacokinetics and ADA is increasingly recognized as a requirement for safe and rational use of biopharmaceuticals. In addition, testing-based strategies rather than empirical dose-escalation may provide more cost-effective use of TNF-antagonists as this allows individualized patient-tailored strategies rather than the current universal approach to anti-TNF biotherapies. The objective of the present minireview - and the accompanying article - is to discuss the reasons for recommending assessments of circulating drug- and ADA levels in patients treated with anti-TNF biopharmaceuticals and to highlight some of the methodological issues that obscure cost-effective and safer ways of using these therapies.
- 8 April 2015
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 6, 152
Open AccessImmunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence
Specific inhibition of the cytokine, tumor necrosis factor-α (TNF), has revolutionized the treatment of patients with several autoimmune diseases, and genetically engineered anti-TNF antibody constructs now constitute a heavy medicinal expenditure. All currently used anti-TNF biopharmaceuticals may lower disease activity and, in some patients, induce remission. Unfortunately, not all patients respond adequately, and safety may be compromised by immunogenicity with the induction of anti-drug-antibodies (ADA). Assessment of drug pharmacokinetics and ADA is increasingly recognized as a requirement for safe and rational use of biopharmaceuticals. In addition, testing-based strategies rather than empirical dose-escalation may provide more cost-effective use of TNF-antagonists as this allows individualized patient-tailored strategies rather than the current universal approach to anti-TNF biotherapies. The objective of the present minireview - and the accompanying article - is to discuss the reasons for recommending assessments of circulating drug- and ADA levels in patients treated with anti-TNF biopharmaceuticals and to highlight some of the methodological issues that obscure cost-effective and safer ways of using these therapies.
- Open Access
- 8 April 2015
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 6, 109
Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection
Immunogenicity of biopharmaceuticals is complex and influenced by both structural and pharmacological factors, and by patient-related conditions such as disease being treated, previous and concomitant therapies and individual immune responsiveness. Essential for tailored therapeutic strategies based on immunopharmacological evidence from individual patients (personalized medicine) is the use of assays for anti-drug antibodies (ADA) that are accurate and relevant in the clinical setting. This paper discusses immunogenicity of genetically engineered immunoglobulins directed against tumor necrosis factor-α (TNF). Emphasis will be on commonly used methods for detection of ADA in human serum including issues that question the clinical applicability of these methodologies. The use of dubious assays for ADA in a clinical context may not only contribute to confusion as to the importance of drug immunogenicity, it may also prevent development of safe and cost-effective ways of using biological TNF-antagonists.
- 8 April 2015
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 6, 109
Open AccessImmunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection
Immunogenicity of biopharmaceuticals is complex and influenced by both structural and pharmacological factors, and by patient-related conditions such as disease being treated, previous and concomitant therapies and individual immune responsiveness. Essential for tailored therapeutic strategies based on immunopharmacological evidence from individual patients (personalized medicine) is the use of assays for anti-drug antibodies (ADA) that are accurate and relevant in the clinical setting. This paper discusses immunogenicity of genetically engineered immunoglobulins directed against tumor necrosis factor-α (TNF). Emphasis will be on commonly used methods for detection of ADA in human serum including issues that question the clinical applicability of these methodologies. The use of dubious assays for ADA in a clinical context may not only contribute to confusion as to the importance of drug immunogenicity, it may also prevent development of safe and cost-effective ways of using biological TNF-antagonists.
- 1 April 2013
- Vol. 15 (83) , 201-211
Personalized Medicine: Theranostics (Therapeutics Diagnostics) Essential for Rational Use of Tumor Necrosis Factor-alpha Antagonists
With the discovery of the central pathogenic role of tumor necrosis factor (TNF)-alpha in many immunoinflammatory diseases, specific inhibition of this pleiotropic cytokine has revolutionized the treatment of patients with several non-infectious inflammatory disorders. As a result, genetically engineered anti-TNF-alpha antibody constructs now constitute one of the heaviest medicinal expenditures in many countries. All currently used TNF antagonists may dramatically lower disease activity and, in some patients, induce remission. Unfortunately, however, not all patients respond favorably, and safety can be severely impaired by immunogenicity, i.e., the ability of a drug to induce anti-drug antibodies (ADA). Assessment of ADA is therefore an important component of the evaluation of drug safety in both pre-clinical and clinical studies and in the process of developing less immunogenic and safer biopharmaceuticals. Therapeutics diagnostics, also called theranostics, i.e., monitoring functional drug levels and neutralizing ADA in the circulation, is central to more effective use of biopharmaceuticals. Hence, testing-based strategies rather than empirical dose-escalation may provide more cost-effective use of TNF antagonists as this allows therapies tailored according to individual requirements rather than the current universal approach to diagnosis. The objective of the present review is to discuss the reasons for recommending theranostics to implement an individualized use of TNF antagonists and to highlight some of the methodological obstacles that have obscured cost-effective ways of using these therapies.
- 1 April 2013
- Vol. 15 (83) , 201-211
Personalized Medicine: Theranostics (Therapeutics Diagnostics) Essential for Rational Use of Tumor Necrosis Factor-alpha Antagonists
With the discovery of the central pathogenic role of tumor necrosis factor (TNF)-alpha in many immunoinflammatory diseases, specific inhibition of this pleiotropic cytokine has revolutionized the treatment of patients with several non-infectious inflammatory disorders. As a result, genetically engineered anti-TNF-alpha antibody constructs now constitute one of the heaviest medicinal expenditures in many countries. All currently used TNF antagonists may dramatically lower disease activity and, in some patients, induce remission. Unfortunately, however, not all patients respond favorably, and safety can be severely impaired by immunogenicity, i.e., the ability of a drug to induce anti-drug antibodies (ADA). Assessment of ADA is therefore an important component of the evaluation of drug safety in both pre-clinical and clinical studies and in the process of developing less immunogenic and safer biopharmaceuticals. Therapeutics diagnostics, also called theranostics, i.e., monitoring functional drug levels and neutralizing ADA in the circulation, is central to more effective use of biopharmaceuticals. Hence, testing-based strategies rather than empirical dose-escalation may provide more cost-effective use of TNF antagonists as this allows therapies tailored according to individual requirements rather than the current universal approach to diagnosis. The objective of the present review is to discuss the reasons for recommending theranostics to implement an individualized use of TNF antagonists and to highlight some of the methodological obstacles that have obscured cost-effective ways of using these therapies.
- 29 November 2012
- Published by Taylor & Francis in Immunotherapy
- Vol. 4 (11) , 1167-1179
Anti-TNF-α Biotherapies: Perspectives for Evidence-Based Personalized Medicine
This article discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with genetically engineered anti-TNF-α immunoglobulin constructs. Arguments why therapeutic decision-making should not rely on clinical outcome alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term therapies with minimal risk of side effects. Large-scale immunopharmacological knowledge of how patients 'handle' TNF-α biopharmaceuticals would also help industry develop more effective and safer TNF-α inhibitors.
- 29 November 2012
- Published by Taylor & Francis in Immunotherapy
- Vol. 4 (11) , 1167-1179
Anti-TNF-α Biotherapies: Perspectives for Evidence-Based Personalized Medicine
This article discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with genetically engineered anti-TNF-α immunoglobulin constructs. Arguments why therapeutic decision-making should not rely on clinical outcome alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term therapies with minimal risk of side effects. Large-scale immunopharmacological knowledge of how patients 'handle' TNF-α biopharmaceuticals would also help industry develop more effective and safer TNF-α inhibitors.
- 19 September 2011
- Vol. 173 (38) , 2337-40
[Innate immunity, autoimmunity and autoinflammation].
T and B lymphocytes of the acquired immune system are functionally superimposed on the evolutionary old innate immune system. The latter recognizes conserved microbial structures through pattern recognition receptors (PRR) which are coactivated by "danger" signals through cytoplasmic PRR termed NOD-like receptors (NLR). These signals include nuclear fragments released by stressed or dying cells. NLR-signalling activates the enzyme caspase-1, which is required for release of pro-inflammatory cytokines such as interleukin (IL)-1ß, IL-18 and IL-33. Dysfunction of innate immunity is central to autoinflammation and may contribute to autoimmunity.
- 19 September 2011
- Vol. 173 (38) , 2337-40
[Innate immunity, autoimmunity and autoinflammation].
T and B lymphocytes of the acquired immune system are functionally superimposed on the evolutionary old innate immune system. The latter recognizes conserved microbial structures through pattern recognition receptors (PRR) which are coactivated by "danger" signals through cytoplasmic PRR termed NOD-like receptors (NLR). These signals include nuclear fragments released by stressed or dying cells. NLR-signalling activates the enzyme caspase-1, which is required for release of pro-inflammatory cytokines such as interleukin (IL)-1ß, IL-18 and IL-33. Dysfunction of innate immunity is central to autoinflammation and may contribute to autoimmunity.
- 19 September 2011
- Vol. 173 (38) , 2340-3
[Danger signals and inflammasomes in autoinflammatory and autoimmune diseases].
Cytoplasmic inflammasomes are formed through activation of pattern recognition receptors (PRR) of the innate immune system. Endogenous and exogenous danger signals, e.g. DNA- and RNA-fragments, urate- and cholesterol crystals, silica and asbestos, ß-amyloid, UV-light and skin irritants, may induce NOD-like receptor protein (NLRP)3 inflammasomes. These inflammasomes govern the induction of proinflammatory cytokines such as IL-1ß, IL-18 and IL-33. PRR and inflammasome dysfunctions may underly immunoinflammatory diseases such as gout and other arthritides, type 1 diabetes and arteriosclerosis.
- 19 September 2011
- Vol. 173 (38) , 2340-3
[Danger signals and inflammasomes in autoinflammatory and autoimmune diseases].
Cytoplasmic inflammasomes are formed through activation of pattern recognition receptors (PRR) of the innate immune system. Endogenous and exogenous danger signals, e.g. DNA- and RNA-fragments, urate- and cholesterol crystals, silica and asbestos, ß-amyloid, UV-light and skin irritants, may induce NOD-like receptor protein (NLRP)3 inflammasomes. These inflammasomes govern the induction of proinflammatory cytokines such as IL-1ß, IL-18 and IL-33. PRR and inflammasome dysfunctions may underly immunoinflammatory diseases such as gout and other arthritides, type 1 diabetes and arteriosclerosis.